Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: Time course of tissue distribution

Toxicon

Volumn 42, Issue 5, 2003, Pages 461-469

  Tang Liu, Diane D S ^a   Aoki, K Roger ^a   Dolly, J Oliver ^b   De Paiva, Anton ^b   Houchen, Tara L ^c   Chasseaud, Leslie F ^c   Webber, Colin ^c  

^a ALLERGAN INC   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Huntington Life Sciences Ltd   (United Kingdom)

Author keywords

900 kDa complex; BoNT A complex, botulinum neurotoxin hemagglutinin complex; BOTOX ; Diffusion; Free BoNT A, free botulinum neurotoxin; Pharmacokinetics; Systemic effects

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; HEMAGGLUTININ; IODINE 125; RADIOACTIVE IODINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG SAFETY; DRUG TISSUE LEVEL; EYELID; FEMALE; GASTROCNEMIUS MUSCLE; LOW DRUG DOSE; MALE; MOLECULAR WEIGHT; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RADIOACTIVITY; RAT; RISK ASSESSMENT; SKIN; THYROID GLAND; TISSUE DISTRIBUTION; ANIMAL; COMPARATIVE STUDY; DIFFUSION; DRUG EFFECT; INTRAMUSCULAR DRUG ADMINISTRATION; KINETICS; METABOLISM; SKELETAL MUSCLE; SPRAGUE DAWLEY RAT;

ORYCTOLAGUS CUNICULUS;

ANIMALS; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; DIFFUSION; EYELIDS; INJECTIONS, INTRAMUSCULAR; IODINE RADIOISOTOPES; KINETICS; MALE; MOLECULAR WEIGHT; MUSCLE, SKELETAL; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 1542601414     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-0101(03)00196-X     Document Type: Article

References (14)

1. Black J.D., Dolly J.O. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J. Cell Biol. 103:(2):1986;535-544.
2. Borodic G.E., Joseph M., Fay L., Cozzolino D., Ferrante R.J. Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck. 12:1990;392-399.
3. Brashear A., Gordon M.F., Elovic E., Kassicieh V.D., Marciniak C., Do M., Lee C.-H., Jenkins S., Turkel C., Botox Post-Stroke Spasticity Study Group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N. Engl. J. Med. 347:(6):2002;395-400.
4. Coffield J.A., Considine R.V., Simpson L.L. The site and mechanism of action of botulinum neurotoxin. Jankovic J., Hallett M. Therapy with Botulinum Toxin. 1994;3-14 Marcel Dekker, New York.
5. Daniels-Holgate P.U., Dolly J.O. Productive and non-productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain. J. Neurosci. Res. 44:(3):1996;263-271.
6. Dolly J.O., Black J., Williams R.S., Melling J. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature. 8:(307):1984;457-460.
7. Frueh B.R., Nelson C.C., Kapustiak J.F., Musch D.C. The effect of omitting botulinum toxin from the lower eyelid in blepharospasm treatment. Am. J. Ophthalmol. 106:1988;45-47.
8. Koman L.A., Mooney J.F., Smith B.P. III, Walker F., Leon J.M., BOTOX Study Group. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. J. Pediatr. Orthop. 20:(1):2000;108-115.
9. ®) in ophthalmology. Surv. Ophthalmol. 36:1991;28-46.
10. Pearce L.B., Borodic G.E., Johnson E.A., First E.R., Maccallum R. The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxicity. Toxicon. 33:(2):1995;217-227.
11. Shaari C.M., Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve. 16:1993;964-969.
12. ® Migraine Clinical Research Group. Botulinum toxin type A as a migraine preventive treatment. Headache. 40:2000;445-450.
13. Simpson L.L. Studies on the binding of botulinum toxin type A to the rat phrenic nerve-hemidiaphragm preparation. Neuropharmacology. 13:1974;683-691.
14. Williams R.S., Tse C.-K., Dolly J.O., Hambleton P., Melling J. Radioiodination of botulinum neurotoxin type A with retention of biological activity and its binding to brain synaptosomes. Eur. J. Biochem. 131:1983;437-445.